ERBB2 and neoplasm: Currently, both types of targets used in CARs show limitations, as follows: overexpressed self-antigens, such as human epidermal growth factor receptor 2 (HER2), are often expressed in healthy tissues, causing on-target off-tumor toxicities [63].